ISSN:
1569-8041
Schlagwort(e):
allogeneic bone marrow transplantation
;
indolent lymphoid neoplasms
Quelle:
Springer Online Journal Archives 1860-2000
Thema:
Medizin
Notizen:
Abstract Background:Allogeneic bone marrow transplantation (BMT) has beenused in patients with low-grade lymphoma (LGL) and chronic lymphocyticleukemia (CLL) with the goal of achieving long-term disease-free survival. Patients and methods:Twenty-nine patients with these diagnoses(LGL = 19, CLL = 10) received allogeneic BMT between September 1995 andJanuary 1999. Median age was 42 (range 20–52) years. Twenty-three oftwenty-nine patients (79%) were Ann Arbor or Rai stage IV at the timeof transplant; twenty-four (83%) had never achieved complete remission(CR). Donor source was HLA-matched sibling (20), unrelated (8) and syngeneic(1). Results:Seventeen patients are currently alive, a median of 29months (range 1–85) post-BMT with a median KPS of 90%.Twenty-three of twenty-seven evaluable patients (85%) achieved CRpost-BMT. Six patients had refractory/recurrent disease. Death occurredrelated to transplant complications in eight patients and underlying diseasein four. Overall and event-free survival for the whole group is 51% and44%, respectively. Conclusions:Allogeneic BMT for young patients with advanced stageLGL or CLL is a feasible strategy that can result in achievement of long-termdisease-free survival.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1023/A:1008379605137
